Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Wall Street validated Endo's diversification thesis — shares rose 8.3% from $30.61 to $33.15 on the announcement, with CEO Holveck framing the deal as…
GEN framed the $1.2B Qualitest acquisition as a forward-thinking move strengthening Endo's market position in the $15B US pain market where >90% of…
GaBI characterized the closed deal as Endo acquiring a generics 'giant' — noting Qualitest's #6 US generics rank by prescriptions and the strategic fit with…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Endo agreed to acquire Qualitest from Apax Partners for $1.2B cash, diversifying into generics. Closed December 1, 2010.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals (this deal) | 2010 | $1.2B | 17 |
| Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation | 2000 | $250M | 34 |
| Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc. | 2009 | $370M | 33 |
| Endo Pharmaceuticals Inc. / SkyePharma plc | 2003 | $120M | 17 |
| Endo Pharmaceuticals Inc. / HealthTronics, Inc. | 2010 | $223M | 17 |
| Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. | 2011 | $2.9B | 13 |
| Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. | 2010 | $144M | 13 |
← Browse all deals · How we score deals
More: 2010 deals · Endo Pharmaceuticals Inc. deals · Other deals